This article was originally published here Lung cancer survival and mortality in Taiwan following the initial launch of targeted therapies: an interrupted time series study. BMJ Open. 2020 May 10;10(5):e033427 Authors: Hsu JC, Wei CF, Yang SC, Lin PC, Lee YC, Lu CY Abstract OBJECTIVES: Two oral targeted therapies, gefitinib and erlotinib, were first approved and then launched into the market for treatment of late-stage non-small cell lung cancer (NSCLC) in Taiwan in 2003 and 2006, respectively.
